Bijal Shah, MD, on CAR T-Cell Therapy in ALL
SOHO 2025
Bijal Shah, MD, of Moffitt Cancer Center, summarizes his presentation on the role of chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia (ALL), touching on its use in the front-line setting for newly diagnosed patients with high risk-features as well as in patients with relapsed or refractory disease. Dr. Shah also discusses the role of measurable residual disease, improving the duration of response after CAR T-cell therapy, how stem cell transplantation fits into this treatment paradigm, and ongoing/upcoming clinical trials in the space.
The ASCO Post Staff
Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretreated population of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and resulted in a response rate of over 80%.
The ASCO Post Staff
Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to target BCR-ABL1, in heavily pretreated patients with chronic myeloid leukemia (CML).
The ASCO Post Staff
Naval G. Daver, MD, of The University of Texas MD Anderson Cancer Center, and Uma Borate, MBBS, of The Ohio State University Comprehensive Cancer Center, give highlights of a lively debate they engaged in at the SOHO meeting. They discuss concomitant vs sequential use of lower-intensity regimens in acute myeloid leukemia (AML), as well as ongoing trials in this space and the role of measurable residual disease.
The ASCO Post Staff
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses TP53 abnormalities in acute lymphoblastic leukemia (ALL), which are uncommon in pediatric patients but may occur in 10% to 15% of adult patients with ALL. Dr. Short reviews recent research into their impact on outcomes, relapse, and the development of secondary cancers, anddiscusses novel therapeutic algorithms being employed.
The ASCO Post Staff
Elias Jabbour, MD, discusses long-term findings and predictors of sustained remission among adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who did not undergo a stem cell transplant, but received the chimeric antigen receptor (CAR) T-cell therapy obecabtagene autoleucel.
